Loading clinical trials...

TERMINATED

Patient Preferences in Making Treatment Decisions in Patients With Stage I-IVA Oropharyngeal Cancer

Patient Preferences in Head and Neck Cancer Treatment Decisions - a Pilot Study of the Durability of Patient Priorities

NCT01949740•University of Chicago

Summary

This pilot research trial studies patient preferences in making treatment decisions in patients with stage I-IVA oropharyngeal cancer. Questionnaires that measure patient priorities before and after treatment may improve the ability to plan for better quality of life in patients with oropharyngeal cancer.

Detailed Description

PRIMARY OBJECTIVES: I. Determine the stability of Head and Neck Priorities Scale (HNPS) ranking between pre- and post-treatment assessments. SECONDARY OBJECTIVES: I. Use patient-interviews to refine and modify the HNPS for use in a larger scale trial. II. Pilot the Head and Neck Patient Outcomes Survey (HNPOS) as a potential tool to identify priorities most important to quality-of-life outcomes. III. Use the Functional Assessment of Cancer Therapy - Head and Neck (FACT-H\&N) and EurolQoL-5D to determine the validity of the HNPOS. OUTLINE: Patients participate in a 45-minute interview comprising assessment of priorities and quality of life at baseline, 1, 6, and 12 months.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Treatment naïve American Joint Committee on Cancer (AJCC) stage I-IVa squamous cell carcinoma of the head and neck with no definitive evidence of metastatic disease
•Sufficient vision, writing, and communication ability to complete the interviews and assessment tool
•Signed informed consent

Exclusion Criteria

•Patients who are enrolled in other head and neck cancer treatment protocols are permitted to participate in this study if a) the other protocol permits this and b) the other protocol does not utilize the HNPS
•Patients who have previously undergone cancer treatment or are presently undergoing additional cancer treatments
•Patients who have already undergone unsuccessful curative-intent surgery on their head and neck cancer
•Patients, who have had a major surgery (defined as requiring general anesthesia but not including tonsillectomy, neck dissection, or panendoscopy \[triple endoscopy or examination under general anesthesia\]), or significant traumatic injury within 4 weeks of the study; patients who have not recovered from the side effects of any of the above surgeries
•Patients unwilling to or unable to comply with the protocol
•Patients unable to communicate with the interviewer

Locations (1)

University of Chicago Comprehensive Cancer Center

Chicago, Illinois, United States

Key Dates

Start Date

June 1, 2013

Primary Completion Date

August 1, 2015

Completion Date

August 1, 2015

Last Updated

September 2, 2015

Enrollment

ACTUAL participants

Conditions

Stage I Squamous Cell Carcinoma of the OropharynxStage II Squamous Cell Carcinoma of the OropharynxStage III Squamous Cell Carcinoma of the OropharynxStage IVA Squamous Cell Carcinoma of the OropharynxTongue Cancer

Interventions

questionnaire administration

OTHER

quality-of-life assessment

PROCEDURE

Freeze-Dried Black Raspberries in Preventing Oral Cancer Recurrence in High At-Risk Appalachian Patients Oral Cancer Survivors

NCT01504932

Stage I Squamous Cell Carcinoma of the Lip and Oral CavityStage I Squamous Cell Carcinoma of the Oropharynx+17 more

View study

COMPLETEDPHASE2

Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

NCT00513435

Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell CarcinomaRecurrent Metastatic Squamous Neck Cancer With Occult Primary+37 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 2, 2015Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Patient Preferences in Making Treatment Decisions in Patients With Stage I-IVA Oropharyngeal Cancer

Inclusion Criteria

Exclusion Criteria

Freeze-Dried Black Raspberries in Preventing Oral Cancer Recurrence in High At-Risk Appalachian Patients Oral Cancer Survivors

Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Gefitinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III or Stage IV Head and Neck Cancer

Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and Neck